🔴 BreakingDrug approvalOPENFDAApr 4
The FDA has approved a new drug called FOUNDAYO (orforglipron), made by Eli Lilly. This approval means the medication is now available for patients to use. The drug was officially approved on April 1, 2026.
WHY IT MATTERSWithout information about which rare disease FOUNDAYO treats, we cannot specify the patient impact — the article lacks details about the condition it addresses or which patients are eligible.
🔴 BreakingDrug approvalOPENFDAApr 3
The FDA has approved a new medication called LIFYORLI (relacorilant) made by Corcept Therapeutics. This drug was officially approved on March 25, 2026. LIFYORLI is a new treatment option that is now available for patients who need it.
WHY IT MATTERSThis approval marks the availability of a new treatment option for patients with Cushing's syndrome, a serious hormonal disorder where the body produces too much cortisol.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by Denali Therapeutics, but the specific name and what disease it treats are not listed in this announcement. The approval was granted on March 24, 2026. Patients and doctors should look for more details from the FDA or the company to understand what this drug does and who it might help.
WHY IT MATTERSWithout knowing the specific drug name and indication, we cannot determine the clinical significance for patients — additional information from the FDA or Denali Therapeutics is needed to assess impact.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug, though the specific name and disease it treats are not listed in this announcement. The drug was developed by MAP77 and received official FDA approval on March 20, 2026. Without more details about what condition this drug treats, it's unclear how it might help patients.
WHY IT MATTERSUnable to determine specific patient impact without knowing the drug name, disease indication, or therapeutic area — this announcement lacks essential details needed to assess relevance to any particular rare disease community.